Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Sees Significant Growth in Short Interest

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF - Get Free Report) saw a significant increase in short interest in October. As of October 15th, there was short interest totalling 1,038,600 shares, an increase of 33.0% from the September 30th total of 780,900 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 10,386.0 days.

Swedish Orphan Biovitrum AB (publ) Price Performance

Shares of OTCMKTS BIOVF traded up $0.51 during trading on Friday, reaching $32.01. The company had a trading volume of 150 shares, compared to its average volume of 784. Swedish Orphan Biovitrum AB has a 52 week low of $19.55 and a 52 week high of $32.25. The business's 50 day moving average price is $29.49 and its 200-day moving average price is $26.90. The stock has a market cap of $9.45 billion, a PE ratio of 53.35 and a beta of 0.56. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.49 and a current ratio of 0.73.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.